Until around 15 years ago, the forecast for spending included nominal annual growth rates of 5-10 per cent, but it was not real. It was not linked to anything. It could not be used to offset new listings because of Budget rules, which remain in place today, and it just made the program a target. It reflects a long-term, enduring dynamic. Nothing will change in the absence of reforming the system's basic architecture.
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Older Australians given three weeks to have their say on in-home aged care services list
November 3, 2026 - - Latest News -
Diabetes scheme registrations fall as health department points to GLP-1 use
November 3, 2026 - - Latest News -
Report finds 196 missing medicines and billions in unreinvested PBS savings
November 3, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News -
Australians with thyroid eye disease gain first PBS subsidised treatment
November 2, 2026 - - Latest News -
‘We are now bridled only by our imagination’. Amgen’s Paul Burton on AI and medicine’s hinge moment
November 2, 2026 - - Latest News -
Edwards Lifesciences opens new Sydney head office as heart valve disease burden grows
November 1, 2026 - - Latest News
